CN1033750C - 用于制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物的中间化合物 - Google Patents

用于制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物的中间化合物 Download PDF

Info

Publication number
CN1033750C
CN1033750C CN94118086A CN94118086A CN1033750C CN 1033750 C CN1033750 C CN 1033750C CN 94118086 A CN94118086 A CN 94118086A CN 94118086 A CN94118086 A CN 94118086A CN 1033750 C CN1033750 C CN 1033750C
Authority
CN
China
Prior art keywords
reaction
compound
formula
mixture
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94118086A
Other languages
English (en)
Chinese (zh)
Other versions
CN1106396A (zh
Inventor
滕田岳
堀越大能
吉冈孝雄
吉冈慎二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CN1106396A publication Critical patent/CN1106396A/zh
Application granted granted Critical
Publication of CN1033750C publication Critical patent/CN1033750C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN94118086A 1991-11-20 1992-11-20 用于制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物的中间化合物 Expired - Fee Related CN1033750C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30458191 1991-11-20
JP304581/91 1991-11-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN92114826A Division CN1034497C (zh) 1991-11-20 1992-11-20 抗糖尿病和抗肥胖症的芳香氨基醇衍生物的制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN96107153A Division CN1054846C (zh) 1991-11-20 1996-06-21 在制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物中的中间化合物的用途

Publications (2)

Publication Number Publication Date
CN1106396A CN1106396A (zh) 1995-08-09
CN1033750C true CN1033750C (zh) 1997-01-08

Family

ID=17934718

Family Applications (3)

Application Number Title Priority Date Filing Date
CN94118086A Expired - Fee Related CN1033750C (zh) 1991-11-20 1992-11-20 用于制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物的中间化合物
CN92114826A Expired - Fee Related CN1034497C (zh) 1991-11-20 1992-11-20 抗糖尿病和抗肥胖症的芳香氨基醇衍生物的制备方法
CN96107153A Expired - Fee Related CN1054846C (zh) 1991-11-20 1996-06-21 在制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物中的中间化合物的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN92114826A Expired - Fee Related CN1034497C (zh) 1991-11-20 1992-11-20 抗糖尿病和抗肥胖症的芳香氨基醇衍生物的制备方法
CN96107153A Expired - Fee Related CN1054846C (zh) 1991-11-20 1996-06-21 在制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物中的中间化合物的用途

Country Status (23)

Country Link
US (3) US5977374A (OSRAM)
EP (1) EP0543662B1 (OSRAM)
JP (2) JP2654323B2 (OSRAM)
KR (1) KR0149679B1 (OSRAM)
CN (3) CN1033750C (OSRAM)
AT (1) ATE143002T1 (OSRAM)
AU (2) AU655689B2 (OSRAM)
CA (1) CA2083323A1 (OSRAM)
CZ (2) CZ280820B6 (OSRAM)
DE (1) DE69213892T2 (OSRAM)
DK (1) DK0543662T3 (OSRAM)
ES (1) ES2094308T3 (OSRAM)
FI (1) FI925255A7 (OSRAM)
GR (1) GR3021245T3 (OSRAM)
HK (1) HK218496A (OSRAM)
HU (1) HUT66816A (OSRAM)
IL (3) IL103825A (OSRAM)
MX (1) MX9206740A (OSRAM)
NO (1) NO179246C (OSRAM)
NZ (1) NZ245188A (OSRAM)
RU (2) RU2095344C1 (OSRAM)
TW (2) TW290543B (OSRAM)
ZA (1) ZA928960B (OSRAM)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
TW363959B (en) * 1994-03-23 1999-07-11 Sankyo Co Thiazolidine and oxazolidine derivatives, their preparation and their medical use
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
WO1995033724A1 (en) * 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9525121D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
GB9525177D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
EP0783888A1 (en) 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
EP0801063B1 (en) * 1996-04-09 2003-01-15 Dr. Reddy's Laboratories Ltd. Thiazolidinedione derivatives having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
BR9711098B1 (pt) 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
US5990169A (en) * 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
GB9706707D0 (en) * 1997-04-02 1997-05-21 Glaxo Group Ltd Chemical compounds
JPH10338679A (ja) * 1997-04-08 1998-12-22 Mitsubishi Rayon Co Ltd チアゾリジン誘導体の製造方法
HUP9702411A2 (hu) * 1997-12-11 2000-03-28 Gyógyszerkutató Intézet Kft. Fenoxi-alkil-amin-származékok és a vegyületeket tartalmazó antiaritmiás hatású gyógyszerkészítmények
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6006419A (en) * 1998-09-01 1999-12-28 Millitech Corporation Synthetic resin transreflector and method of making same
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
GB9929297D0 (en) * 1999-12-11 2000-02-02 Glaxo Group Ltd Process
AU4116801A (en) * 2000-03-17 2001-09-24 Ajinomoto Kk Drugs for complications of diabetes and neuropathy and utilization thereof
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
NZ533997A (en) * 2000-07-13 2005-11-25 Sankyo Co Amino alcohol derivatives
CA2423792A1 (en) 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
EP1383729A4 (en) * 2001-04-05 2006-04-19 Smithkline Beecham Corp DEFORMYLASE PEPTIDE INHIBITORS
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
WO2003010157A1 (en) * 2001-07-23 2003-02-06 Dr. Reddy's Research Foundation Dioxane derivatives and a process for their preparation
EP1452521A4 (en) 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
MXPA04008298A (es) 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
KR101071748B1 (ko) * 2003-12-23 2011-10-11 아스텔라스세이야쿠 가부시키가이샤 아미노알콜 유도체
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
CN101111266A (zh) * 2005-01-31 2008-01-23 味之素株式会社 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2009052693A1 (fr) 2007-10-24 2009-04-30 Zhu, Xiaoying Dispositif d'écran à enroulement
NZ585073A (en) * 2007-11-01 2012-08-31 Howard Florey Inst Aryloxy amine compounds and their use as sodium channel modulators
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
US9968531B2 (en) 2015-08-05 2018-05-15 Dupont Tate & Lyle Bio Products Company, Llc Deodorants containing 1,3-propanediol
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
KR102054399B1 (ko) * 2018-03-26 2019-12-10 주식회사 프로텍바이오 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3976783A (en) * 1970-07-18 1976-08-24 Pfizer Inc. Method of stimulating the heart employing ureido substituted phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives
GB1551260A (en) * 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
DE3061205D1 (en) * 1979-06-16 1983-01-05 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
DE3061334D1 (en) * 1979-06-16 1983-01-20 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
EP0025331B1 (en) * 1979-09-06 1983-03-02 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
DE3368258D1 (en) * 1982-07-16 1987-01-22 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
GB8620951D0 (en) * 1986-08-29 1986-10-08 Beecham Group Plc Compounds
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
GB8910374D0 (en) * 1989-05-05 1989-06-21 Ici Plc Chemical compounds
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
DK0597102T3 (da) * 1991-07-30 1999-08-09 Yamanouchi Pharma Co Ltd Nyt bisheterocyklisk derivat og salt heraf samt hypoglykæmisk sammensætning
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
US5635534A (en) 1997-06-03
KR0149679B1 (ko) 1998-10-15
EP0543662A3 (en) 1993-08-11
NO924440L (no) 1993-05-21
EP0543662B1 (en) 1996-09-18
CN1034497C (zh) 1997-04-09
US5576340A (en) 1996-11-19
CZ280328B6 (cs) 1995-12-13
CZ34595A3 (en) 1996-04-17
DE69213892D1 (de) 1996-10-24
NO179246B (no) 1996-05-28
TW233294B (OSRAM) 1994-11-01
DK0543662T3 (OSRAM) 1997-03-03
ATE143002T1 (de) 1996-10-15
DE69213892T2 (de) 1997-04-17
RU2095344C1 (ru) 1997-11-10
MX9206740A (es) 1993-05-31
JP2654323B2 (ja) 1997-09-17
AU7751894A (en) 1995-01-12
RU94036004A (ru) 1996-07-10
NZ245188A (en) 1994-07-26
NO179246C (no) 1996-09-04
KR930009982A (ko) 1993-06-21
US5977374A (en) 1999-11-02
FI925255A0 (fi) 1992-11-19
FI925255L (fi) 1993-05-21
IL103825A (en) 1998-04-05
CA2083323A1 (en) 1993-05-21
NO924440D0 (no) 1992-11-18
EP0543662A2 (en) 1993-05-26
IL103825A0 (en) 1993-04-04
CN1073428A (zh) 1993-06-23
IL110804A0 (en) 1994-11-11
IL110804A (en) 1997-07-13
HUT66816A (en) 1995-01-30
ES2094308T3 (es) 1997-01-16
RU2081113C1 (ru) 1997-06-10
HU9203638D0 (en) 1993-01-28
AU655689B2 (en) 1995-01-05
TW290543B (OSRAM) 1996-11-11
FI925255A7 (fi) 1993-05-21
CZ343692A3 (en) 1993-12-15
CN1106396A (zh) 1995-08-09
JPH0625118A (ja) 1994-02-01
CZ280820B6 (cs) 1996-04-17
CN1151401A (zh) 1997-06-11
JP2991985B2 (ja) 1999-12-20
HK218496A (en) 1996-12-27
AU2849392A (en) 1993-05-27
ZA928960B (en) 1993-05-19
CN1054846C (zh) 2000-07-26
AU670007B2 (en) 1996-06-27
JPH09188669A (ja) 1997-07-22
GR3021245T3 (en) 1997-01-31

Similar Documents

Publication Publication Date Title
CN1054846C (zh) 在制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物中的中间化合物的用途
EP1840125B1 (fr) Intermédiaires pour la production de dioxane-2-alkylcarbamates
CN1108239A (zh) 杀虫(菌)剂及其中间体的制备方法
CN1119321C (zh) 手性β－氨基酸的不对称合成
CN1042705A (zh) 3，5-二甲基-4-甲氧基吡啶衍生法及用于该制法的新型中间产物
CN1218935C (zh) 取代苯甲酰脲类昆虫生长调节剂的合成方法
CN1111156C (zh) α,α＇—二氨基醇及其制备方法
CN1396168A (zh) (甲基)丙烯酸硅烷酯的制造方法
CN1015172B (zh) 卤化-3-卤代-2-羟基丙基三甲基铵的制备方法
CN1329598A (zh) 制备4－羟基喹啉类化合物和/或其互变异构体的方法
CN101054355A (zh) 光学纯双亚磺酰胺化合物及其应用
CN1927830A (zh) 光学纯亚磺酰胺化合物及其应用
EP0663901B1 (fr) Procede de preparation stereoselective d'un derive de la beta-phenylisoserine et son utilisation pour la preparation de derives du taxane
EP1907396B1 (fr) Procede de preparation de la 4 -amino-4'-demethyl-4-desoxypodophyllotoxine
CN1835918A (zh) 外消旋2－{[2－(4－羟基苯基)乙基]硫基}－3－[4－(2－{4－[(甲磺酰基)氧基]苯氧基}乙基)苯基]－丙酸的制备方法
CN1304346C (zh) 光学活性2，3－联烯醇和联烯醇酯、合成方法及其用途
CN1118161A (zh) 通过使相应的醛肟脱水制备邻羟基取代的芳族腈类的方法
CN101065387A (zh) 含磷酰胆碱基的化合物及其制备方法
CN101044130A (zh) 一种制备缩水甘油衍生物的方法
CN1167980C (zh) 定时释放显影抑制基黄成色剂及其制备
CN1876644A (zh) 一种(4R－cis)－6－甲酰基－2,2－二甲基－1,3－二氧己环－4－乙酸叔丁酯的合成方法
CN1154355A (zh) 异香草醛的制备方法
CN1660766A (zh) 带手性甲基侧链的ω－羟基酸衍生物
CN1219758C (zh) 一种光学纯二叔丁基亚磺酸硫酯的制备方法
CN1380279A (zh) (4－炔基)－芳香酮酸类化合物、合成方法及应用

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee